An Intraperitoneal Injection Technique in Adult Zebrafish that Minimizes Body Damage and Associated Mortality.


Journal

Journal of visualized experiments : JoVE
ISSN: 1940-087X
Titre abrégé: J Vis Exp
Pays: United States
ID NLM: 101313252

Informations de publication

Date de publication:
29 Mar 2024
Historique:
medline: 15 4 2024
pubmed: 15 4 2024
entrez: 15 4 2024
Statut: epublish

Résumé

The adult zebrafish (Danio rerio), which is genetically accessible, is being employed as a valuable vertebrate model to study human disorders such as cardiomyopathy. Intraperitoneal (IP) injection is an important method that delivers compounds to the body for either testing therapeutic effects or generating disease models such as doxorubicin-induced cardiomyopathy (DIC). Currently, there are two methods of IP injection. Both methods have limitations when handling toxic compounds such as doxorubicin, which result in side effects manifesting as severe damage to the body shape and fish death. While these shortcomings could be overcome by extensive investigator training, a new IP injection method that has minimal side effects is desirable. Here, a unique IP injection method that is able to handle toxic compounds is reported. Consistently reduced cardiac function can result without incurring significant fish death. The technique can be easily mastered by researchers who have minimal experience with adult zebrafish.

Identifiants

pubmed: 38619251
doi: 10.3791/66500
doi:

Types de publication

Journal Article Video-Audio Media

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Maryam Moossavi (M)

Department of Biochemistry and Molecular Biology, Mayo Clinic; Department of Cardiovascular Medicine, Mayo Clinic.

Hong Zhang (H)

Cardiovascular Surgery Department, Guilin Hospital of 2nd Xiangya Hospital, Central South University; Cardiovascular Surgery Department, 2nd Xiangya Hospital, Central South University; xyzhanghong@hotmail.com.

Jiarong Li (J)

Department of Biochemistry and Molecular Biology, Mayo Clinic; Department of Cardiovascular Medicine, Mayo Clinic; Cardiovascular Surgery Department, 2nd Xiangya Hospital, Central South University.

Feixiang Yan (F)

Department of Biochemistry and Molecular Biology, Mayo Clinic; Department of Cardiovascular Medicine, Mayo Clinic.

Xiaolei Xu (X)

Department of Biochemistry and Molecular Biology, Mayo Clinic; Department of Cardiovascular Medicine, Mayo Clinic; xu.xiaolei@mayo.edu.

Classifications MeSH